Astrazeneca (AZN) Gross Margin (2009 - 2026)

Astrazeneca has reported Gross Margin for 18 years, with the latest figure at 83.6% in Q2 2026.

• On a quarterly basis, Gross Margin rose 66.0% year-over-year to 83.6% in Q2 2026; TTM through Jun 2026 was 82.0%, a 78.0% decrease from a year earlier, with the FY2025 full-year figure at 82.04%, down 50.0% from the prior year.
• Gross Margin was 83.6% for Q2 2026 at Astrazeneca, up from 82.9% in the prior quarter.
• The five-year high for Gross Margin was 86.9% in Q2 2023, with the low at 69.17% in Q1 2022.
• Average Gross Margin over 5 years is 80.95%, with a median of 82.92% recorded in 2025.
• The sharpest annual moves came in 2023 and 2024: Gross Margin surged 1576 bps in 2023, then sank 766 bps in 2024.
• Over 5 years, Gross Margin stood at 74.12% in 2022, then climbed by 16 bps to 85.71% in 2023, then rose by 1 bps to 86.43% in 2024, then dropped by 8 bps to 79.92% in 2025, then rose by 5 bps to 83.6% in 2026.
• The last three Gross Margin figures came in at 83.6% (Q2 2026), 82.9% (Q1 2026), and 79.92% (Q4 2025), per Business Quant data.